Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Completed · Phase 2

Conditions studied: Recurrent Melanoma, Stage IV Melanoma

In brief

Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2 in treating patients who have advanced melanoma. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Melanoma vaccine plus interleukin-2 may kill more cancer cells

Key facts

Study ID
NCT00005949
Run by
National Cancer Institute (NCI)
People needed
50
Starts
2001-03-01
Last updated by the study team
2013-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.